Skip to main content
[Preprint]. 2023 Aug 28:2023.08.26.554851. [Version 1] doi: 10.1101/2023.08.26.554851

Fig. 4 |. Validation of differential potency predictions.

Fig. 4 |

(a-d) In vitro dose-response relationships of HCC1806-Par differentially potent compounds and (e-f) MDA-MB-231-Par differentially potent compounds. 95% confidence intervals. (g) Relationship between the predicted and observed differences in IC50 values of tested compounds between HCC1806-Par and MDA-MB-231-Par cell lines. Two-sided t-test.